US7170811035 - Common Stock

We assign a fundamental rating of **6** out of 10 to **PFE**. **PFE** was compared to 202 industry peers in the **Pharmaceuticals** industry. While **PFE** has a great profitability rating, there are some minor concerns on its financial health. **PFE** is valued quite cheap, but it does not seem to be growing. Finally **PFE** also has an excellent dividend rating. This makes **PFE** very considerable for value and dividend investing!

Each year in the past 5 years **PFE** has been profitable.

Of the past 5 years **PFE** 4 years had a positive operating cash flow.

The **Return On Assets** of **PFE** (**4.87%**) is better than **89.00%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.87% | ||

ROE | 10.81% | ||

ROIC | 9.08% |

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

Looking at the **Operating Margin**, with a value of **27.00%**, **PFE** belongs to the top of the industry, outperforming **94.00%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **PFE** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 27% | ||

PM (TTM) | 15.29% | ||

GM | 69.03% |

OM growth 3Y-7.83%

OM growth 5Y0.46%

PM growth 3Y-45.95%

PM growth 5Y-33.24%

GM growth 3Y-4.36%

GM growth 5Y-2.32%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **PFE** is still creating some value.

With a decent **Altman-Z score** value of **2.44**, **PFE** is doing good in the industry, outperforming **71.00%** of the companies in the same industry.

A Debt/Equity ratio of **0.63** indicates that **PFE** is somewhat dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.63 | ||

Debt/FCF | 7.78 | ||

Altman-Z | 2.44 |

ROIC/WACC1.07

WACC8.47%

The **Current ratio** of **PFE** (**2.38**) is worse than **64.00%** of its industry peers.

The **Quick ratio** of **PFE** (**2.05**) is worse than **60.50%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.38 | ||

Quick Ratio | 2.05 |

The earnings per share for **PFE** have decreased strongly by **-56.32%** in the last year.

Measured over the past years, **PFE** shows a decrease in **Earnings Per Share**. The EPS has been decreasing by **-9.41%** on average per year.

The Revenue for **PFE** has decreased by **-31.24%** in the past year. This is quite bad

Measured over the past years, **PFE** shows a small growth in **Revenue**. The Revenue has been growing by **7.46%** on average per year.

EPS 1Y (TTM)-56.32%

EPS 3Y-12.38%

EPS 5Y-9.41%

EPS growth Q2Q-109.55%

Revenue 1Y (TTM)-31.24%

Revenue growth 3Y11.76%

Revenue growth 5Y7.46%

Revenue growth Q2Q-41.55%

The **Revenue** is expected to grow by **1.99%** on average over the next years.

EPS Next Y25.32%

EPS Next 2Y22.83%

EPS Next 3Y26.63%

EPS Next 5Y15.13%

Revenue Next Year2.93%

Revenue Next 2Y3.81%

Revenue Next 3Y3.1%

Revenue Next 5Y1.99%

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

With a **Price/Earnings** ratio of **9.47**, the valuation of **PFE** can be described as very reasonable.

92.50% of the companies in the same industry are more expensive than **PFE**, based on the **Price/Earnings** ratio.

A **Price/Forward Earnings** ratio of **11.85** indicates a reasonable valuation of **PFE**.

Based on the **Price/Forward Earnings** ratio, **PFE** is valued cheaply inside the industry as 87.00% of the companies are valued more expensively.

The average S&P500 **Price/Forward Earnings** ratio is at **21.49**. **PFE** is valued slightly cheaper when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 9.47 | ||

Fwd PE | 11.85 |

96.00% of the companies in the same industry are more expensive than **PFE**, based on the **Enterprise Value to EBITDA** ratio.

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **PFE** indicates a rather cheap valuation: **PFE** is cheaper than 84.50% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 18.76 | ||

EV/EBITDA | 5.34 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

The decent profitability rating of **PFE** may justify a higher PE ratio.

PEG (NY)0.37

PEG (5Y)N/A

EPS Next 2Y22.83%

EPS Next 3Y26.63%

With a **Yearly Dividend Yield** of **6.10%**, **PFE** is a good candidate for dividend investing.

Compared to an average industry **Dividend Yield** of **4.27**, **PFE** pays a better dividend. On top of this **PFE** pays more dividend than 98.00% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 6.1% |

The dividend of **PFE** has a limited annual growth rate of **4.69%**.

Dividend Growth(5Y)4.69%

Div Incr Years13

Div Non Decr Years13

The dividend of **PFE** is growing, but earnings are growing more, so the dividend growth is sustainable.

DP87.55%

EPS Next 2Y22.83%

EPS Next 3Y26.63%

**PFIZER INC**

NYSE:PFE (2/26/2024, 7:04:00 PM)

Premarket: 27.22 +0.04 (+0.15%)**27.18**

**-0.58 (-2.09%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap153.47B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 6.1% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 9.47 | ||

Fwd PE | 11.85 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.37

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 4.87% | ||

ROE | 10.81% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 27% | ||

PM (TTM) | 15.29% | ||

GM | 69.03% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.32

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.63 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.38 | ||

Quick Ratio | 2.05 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-56.32%

EPS 3Y-12.38%

EPS 5Y

EPS growth Q2Q

EPS Next Y25.32%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-31.24%

Revenue growth 3Y11.76%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y